JFLB(SZ:002762) Zheng Quan Shi Bao Wang·2025-07-14 06:57Core Viewpoint - *ST Jinbi is expected to achieve significant revenue growth in the first half of 2025, with projected revenues between 160 million to 170 million yuan, representing an increase of 104.45% to 117.23% compared to the same period last year [1][2] Group 1: Revenue Growth - The revenue growth in the first half of 2025 is crucial for the company to meet its annual performance targets, as it accounts for approximately 70% to 75% of the total revenue achieved in 2024, which was 225 million yuan [1] - The medical beauty service segment, particularly through its subsidiaries in Zhuhai and Zhongshan, is expected to contribute around 33 million yuan in revenue for the first half of 2025, highlighting its growth potential [1] - The company has actively transformed its product segment by increasing investments in e-commerce channels and adjusting its product structure to better meet market demands, which has successfully driven revenue growth [1] Group 2: Financial Outlook - Despite the anticipated revenue growth, *ST Jinbi is projected to incur a net loss attributable to shareholders of between 8 million to 16 million yuan in the first half of 2025, primarily due to investment losses from its stake in Guangdong Hanfei Hospital [2] - The company has been under delisting risk warning since April 24 due to negative net profit and revenue below 300 million yuan for 2024, but the recent revenue forecast lays a foundation for potential removal of this warning in the future [2] - Long-term profitability is expected to improve as the company continues to expand and optimize its business operations, focusing on cost control and business integration [2]